0.5600 +0.01 (1.28%)
After hours: 7:58PM EST
|Bid||0.5600 x 900|
|Ask||0.5515 x 3000|
|Day's Range||0.5201 - 0.5535|
|52 Week Range||0.4100 - 3.7200|
|Beta (5Y Monthly)||2.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.00|
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has received approximately $1.0 million funding from the National Institutes of Health (NIH) to cover the first year of a two-year Phase 2 federal grant. Novan is eligible to receive approximately $500,000 of additional funding for the second year, subject to availability of NIH funds and satisfactory progress of the project.
Novan, Inc. (“the Company” or “Novan”) (NOVN) today provided an update on several aspects of its Phase 3 B-SIMPLE program (B-SIMPLE1 and B-SIMPLE2). Novan has been granted a Type C meeting with the U.S. Food and Drug Administration (“FDA”) on April 1, 2020. The Type C Meeting is to seek FDA feedback on the proposal to conduct one additional, well-controlled confirmatory study of SB206 to support a future New Drug Application (“NDA”).
Novartis AG said Wednesday that net income fell 5.9% in the final quarter of the year, hit by tax charges, but guided for growth in both sales and profit in 2020.
A Triangle drugmaker's stock has declined sharply following poor trial results, but company officials plan to move forward with their lead drug candidate.
Shares of Novan Inc. fell 72% in premarket trading on Friday after the biotechnology company said Thursday that its experimental treatment for molluscum contagiosum, a type of skin infection, had failed to meet the primary endpoints in two late-stage clinical trials. Novan also said it only has enough cash to support operations through the first quarter of this year. However, the company said it still has plans to use data from one of the trials for SB206 a new drug application submission to the Food and Drug Administration, by launching a confirmatory Phase-3 trial in April. Novan's stock is up 26% over the last three months. The S&P 500 has gained 12% during the same timeframe.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the ...
Statistical significance was not achieved for the primary endpoint in either B-SIMPLE1 or B-SIMPLE2, however multiple sensitivity analyses are supportive and consistent across both studies and support a potential path forward for the asset. The two trials are ongoing, awaiting 24-week safety data, thus the top-line results are for efficacy data only.
After being promoted into a new leadership role at the start of 2019, a Triangle executive has now been tapped as the next CEO of a Morrisville-based drugmaker.
Novan, Inc. (“the Company” or “Novan”) (NOVN) today announced that Paula Brown Stafford, currently President and Chief Operating Officer (“COO”) of Novan, will succeed G. Kelly Martin as its Chief Executive Officer (“CEO”), effective February 2, 2020, and she will remain a member of the Novan Board of Directors. Mr. Martin, as per previous agreement, has a fixed term employment contract that is due to expire on February 1, 2020 and Mr. Martin will step down as Novan's CEO at that time.
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]
Novan (NOVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has submitted a request for a pre-IND meeting with the U.S. Food and Drug Administration (FDA) for new product candidate, SB207. The Company anticipates that the meeting will be held in December 2019. Novan has identified targeted viral opportunities of high unmet need where the Company’s nitric oxide releasing technology could provide clinical benefit to patients.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company’s Phase 2 molluscum study, designed to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum, has been published in the Journal of the American Academy of Dermatology (“JAAD”). In this Phase 2 study, SB206 demonstrated clinical efficacy with a favorable safety profile. “The publication of this Phase 2 study through a prestigious platform such as JAAD underscores Novan’s innovative nitric-oxide technology and provides exposure to the results that supported our decision to progress into a Phase 3 molluscum program.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has received a grant from the U.S. Department of Defense’s (DoD) Congressionally Directed Medical Research Programs (CDMRP) of approximately $1.1 million as part of its Peer Reviewed Cancer Research Program. The grant will support the development of a product candidate (WH504) for the treatment of cervical intraepithelial neoplasia (CIN), with well-characterized physical chemical properties suitable for intravaginal administration.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Compensation Committee of Novan’s Board of Directors granted stock options to purchase an aggregate of 25,000 shares of its common stock to a newly-hired employee with a grant date of September 6, 2019. The stock options were granted as an inducement material to the new employee entering into employment with Novan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $2.62 per share, the closing price of Novan’s common stock on September 6, 2019.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced the appointment of Michelle Patterson as Vice President of Project Management. In this centrally positioned role, Ms. Patterson will manage the delivery of key product portfolio milestones by integrating work activity across Novan’s business functions including regulatory, pre-clinical, clinical, manufacturing and CMC. Ms. Patterson will lead the cross-functional coordination and orchestration of integrated project plans for the SB206 New Drug Application (“NDA”) submission, should the Phase 3 clinical program in molluscum contagiosum be positive.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that it will participate in the H.C. Wainwright 21st Annual Global Investment Conference in New York on Monday, September 9, 2019. Participation will include a Company presentation as well as a Q&A session. The Company will also have a number of one-on-one meetings with investors during the conference.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has received a federal grant from the National Institutes of Health (NIH). In addition, the Company anticipates receiving an additional federal grant in the very near term.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has executed a non-binding letter of intent (LOI) with a third party on its facility at 4105 Hopson Road in Morrisville, NC. The primary goal of the LOI is to negotiate an agreement that obtains the release of Novan from its current multi-year obligation. The Company’s objective is to reach a binding agreement no later than the end of the third quarter of 2019.